Toronto, Ontario – Jan 07, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, today is pleased to release the Company Quarterly Newsletter. The Newsletter provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study. The Newsletter can be found on the Company’s website www.theralase.com/invest/. To receive future Newsletters, please contact info@theralase.com. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. Additional information is available at www.theralase.com and www.sedar.com Forward-Looking Information This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and … Read More

TORONTO, ON/ November 29, 2019 / Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, today released financial results for the nine-month period ended September 30, 2019. Financial Highlights: Condensed Consolidated Statements of Operations (Unaudited) Three-Month Ended Sep 30 Nine-Month Ended Sep 30 In Canadian Dollars 2019 2018 2019 2018 Total Revenues $144,455 $365,940 $514,891 $1,276,630 Cost of sales $106,396 $126,975 $374,040 $559,296 Gross margin $38,059 $238,965 $140,851 $717,334 As percentage of revenue 26% 65% 27% 56% Net loss ($1,786,777) ($722,817) ($4,399,045) ($2,612,168) Loss per share ($0.01) ($0.006) ($0.03) ($0.02) Total revenue for the nine-month period ended September 30, 2019 decreased to $514,891 from $1,276,630 for the same period in 2018, a 60% decrease. In Canada, revenue decreased 44% to $477,502 from … Read More

Toronto, Ontario – November 27, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce several scientific recognitions. The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase’s Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy (“PDT”) metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future. The review article, titled “Metal-Based photosensitizers for photodynamic therapy – the future of multimodal oncology?”, is available online at www.sciencedirect.com and will be published in a special issue of Current Opinion in Chemical Biology entitled Next … Read More

Toronto, Ontario – October 31, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the departure of its Chief Executive Officer – Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer – Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth. “We thank Kipton for his contributions to the Company over the last 8 months and we wish him well,” said Theralase Technologies Chairman of the Board of Directors, Guy Anderson.  “We are also excited  with the prospects of the TLD-1433 Anti-Cancer Technology (“ACT”) platform  as it has the potential … Read More

Toronto, Ontario – October 22, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Company has been granted a European Patent for their anti-cancer PDCs, which will issue in due course. The patent entitled, “Metal-Based Thiophene Photodynamic Compounds and Their Use” advances Theralase’s intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (“ACT”) platform. The patent encompasses an extensive library of PDCs, including Theralase’s lead PDC, TLD-1433, approved by Health Canada to be evaluated in a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”). Currently, Study II has successfully been launched in 3 Canadian clinical oncology sites with 2 patients treated.   The Company has … Read More

Toronto, Ontario – October 07, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced that London Health Sciences Centre (“LHSC”) Research Ethics Board (“REB”) has approved the commencement of a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study to enroll and treat patients who present with Carcinoma In-Situ (“CIS”) and who are considered Bacillus Calmette-Guerin (“BCG”)-Unresponsive or are intolerant to BCG Therapy (“Study II”). LHSC is recognized as one of Canada’s leading cancer research centres ranking, in the top ten of Canada’s research hospitals. LHSC’s research institute is affiliated with the University of Western Ontario and is responsible for training the next generation of medical professionals, while leading Ontario research into the latest medical technologies. Dr. Joseph Chin, MD, FRSC, Professor of … Read More

Toronto, Ontario – October 01, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to announce today that the Company has filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) to initiate a Phase II, Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) of Theralase’s anti-cancer Photo Dynamic Therapy (“PDT”) technology in patients using the Companies patented PDC, TLD-1433 combined with it’s proprietary TLC-3200 medical laser system. Study II, entitled, “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Bacillus Calmette-Guerin (“BCG”) unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Patients or Patients who are Intolerant to BCG Therapy” was successfully launched at the University Health Network (“UHN”) … Read More

Toronto, Ontario – September 30, 2019, Theralase®  Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that patient six, enrolled and treated in the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study”), has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 540 day clinical and cystoscopy assessment. Patient six has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540 days post treatment clinical cystoscopy assessment and urine cytology, marking a new milestone for the Company. Shawn Shirazi, Ph.D., Chief Executive Officer – Drug Division, Theralase stated “I’m excited to share the current cancer-free status of patient 6 which … Read More

TORONTO, ON / September 13, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage biopharmaceutical company developing Anti-Cancer treatments with their light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, today announces the grant of stock options. The Company has granted an aggregate of 12,340,000 stock options to directors, officers, employees & advisory board members pursuant to the Company’s stock option plan.  Of the options granted, 2,340,000 options are exercisable ata price of CDN$0.50 per share and 10,000,000 options are exercisable at a price of CDN$0.25 per share. All of the options vest over a three year period and expire five years from the date of the grant. The stock option plan was last approved by the shareholders of the Company at the Annual General and Special Meeting of Shareholders held on June 27, 2019. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company … Read More

TORONTO, ON / ACCESSWIRE / September 4, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage biopharmaceutical company developing Anti-Cancer treatments with their light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today that, the first patient has been treated in its Phase II clinical study titled “A Phase II Clinical Study of Intravesical Photodynamic Therapy (“PDT”) in Patients with Bacillus Calmette Guérin (“BCG”) Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) or Patients who are Intolerant to BCG Therapy (“Study II”)” at University Health Network (“UHN”) in Toronto. This marks the official launch of Study II which focuses on the treatment of approximately 100 BCG-Unresponsive NMIBC patients presenting with Carcinoma In-Situ (“CIS”)in approximately 20 clinical study sites located in Canada and the US, with a primary endpoint of efficacy at any point in time, measured by Complete Response (“CR”), a secondary endpoint of duration … Read More